Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Public Outcry Prompts Novartis To Cancel Vasella Non-Compete Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis drops plan to pay outgoing chairman Daniel Vasella $78 million to stop him working for competitors, bowing to growing concerns in Switzerland over executive compensation.

You may also be interested in...



European Notebook: A Smooth Succession At Roche, EMA’s New Leadership Team, A Medicine Bank In Greece, Atorvastatin Price Drop In Ireland

Lufthansa's Christoph Franz will become Roche’s chairman next year; more restructuring details emerge from the European Medicines Agency; pharma companies donate medicines in Greece; Ireland names preferred medicines and aims to cut atorvastatin price.

European Notebook: Shake-Up At EMA, Restructuring At Pierre Fabre, Reinhardt Returns To Novartis

A new leadership team at EMA to be unveiled in September; the death of Pierre Fabre leads to management restructuring at France's third largest pharma; Reinhardt to review strategy as he replaces Vasella at the Swiss multinational, Novartis; and more…

Bayer’s Reinhardt Returning To Novartis To Replace Departing Vasella

Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel